Modulated TRPC1 expression predicts sensitivity of breast cancer to doxorubicin and magnetic field therapy: segue towards a precision medicine approach.
Y. K. Tai, K. K. W. Chan, C. H. H. Fong, S. Ramanan, J. L. Y. Yap, J. N. Yin, Y. S. Yip, W. R. Tan, A. P. F. Koh, N. S. Tan, C. W. Chan, R. Y. J. Huang, A. Franco-Obregon
This study shows TRPC1 expression predicts breast cancer sensitivity to doxorubicin and PEMF therapy, suggesting TRPC1 as a biomarker for precision medicine approaches.
Frontiers in Oncology · Jan 24, 2022Peer-reviewedCancer Biology